Stocks Health care JNJ
NYSE · Health careJohnson & Johnson (JNJ)
Johnson & Johnson brought in $97.9B of revenue over the twelve months to June 28, 2026, up 8.1% from a year earlier. Net income was $21B, a net margin of 21.5%. Operating cash flow minus capital spending left $19.7B of free cash flow in fiscal 2025. At June 28, 2026 it held $20.4B in cash against $37.3B of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on July 23, 2026.
Key facts about Johnson & Johnson
- Net worth
- Johnson & Johnson has a market value (market cap) of $635.6B at the latest share price, and shareholders' equity of $85B on its balance sheet at June 28, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $94.2B (+6.0% year on year), with net income of $26.8B. Over the 12 months to June 28, 2026: revenue $97.9B, net income $21B.
- Cash flow
- In fiscal 2025 operations brought in $24.5B of cash; after $4.8B of capital spending, free cash flow was $19.7B.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on July 23, 2026 and covers the period to June 28, 2026. Open on SEC EDGAR
- Next earnings report
- Johnson & Johnson's next report is expected around October 13, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
- Dividend
- Johnson & Johnson paid dividends of $5.14 per share in fiscal 2025, a yield of 1.95% at the current price.
What Johnson & Johnson does
Johnson & Johnson researches, develops, and manufactures prescription pharmaceuticals and medical devices. Its products include medicines for immunology, oncology, and infectious diseases, as well as surgical instruments and orthopedic implants. These are sold to hospitals, physicians, and pharmacies. The company is known for medical technology and healthcare products. Its shares trade on NYSE under the ticker JNJ.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $94.2B | $26.8B | $11.03 | $19.7B |
| 2024 | $88.8B | $14.1B | $5.79 | $19.8B |
| 2023 | $85.2B | $35.2B | $13.72 | $18.2B |
| 2022 | $80B | $17.9B | $6.73 | $17.2B |
| 2021 | $78.7B | $20.9B | $7.81 | $19.8B |
| 2020 | $82.6B | $14.7B | $5.51 | $20.2B |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where JNJ ranks in Health care
Dividends
Johnson & Johnson paid $5.14 per share in fiscal 2025. At the current price that is a yield of 1.95%. It paid out $12.4B in cash dividends, 46% of its net income.
| Fiscal year | Per share | Paid out | Of profit |
|---|---|---|---|
| 2025 | $5.14 | $12.4B | 46% |
| 2024 | $4.91 | $11.8B | 84% |
| 2023 | $4.70 | $11.8B | 33% |
| 2022 | $4.45 | $11.7B | 65% |
| 2021 | $4.19 | $11B | 53% |
| 2020 | $3.98 | $10.5B | 71% |
Latest SEC filings
What Johnson & Johnson has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 11, 2026Form N-PX filing N-PX
- August 6, 2026Form 13F-HR filing 13F-HR
- August 4, 2026
- July 29, 2026
- July 28, 2026
- July 23, 2026Quarterly report 10-Q · period to June 28, 2026Revenue rose 6.6% to $25.3B versus the same quarter last year; diluted EPS $2.27 versus $2.29.
- July 15, 2026
- June 25, 2026
- June 25, 2026
- May 27, 2026
What is JNJ worth? A DCF from its reported cash flow
Insider trades
What the people running Johnson & Johnson did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $67.8M worth of shares in the last 90 days and bought none on the open market.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 2, 2026 | Schmid TimothyEVP, WW Chair, MedTech | Exercised options | 11,070 | $1.5M |
| September 2, 2026 | Schmid TimothyEVP, WW Chair, MedTech | Sold | 11,070 | $3M |
| September 2, 2026 | Schmid TimothyEVP, WW Chair, MedTech | Exercised options | 22,527 | $3.4M |
| September 2, 2026 | Schmid TimothyEVP, WW Chair, MedTech | Sold | 22,527 | $6.2M |
| August 17, 2026 | Taubert Jennifer LEVP, WWC. Innovative Medicine | Exercised options | 15,000 | $1.7M |
| August 17, 2026 | Taubert Jennifer LEVP, WWC. Innovative Medicine | Sold | 15,000 | $4M |
| August 13, 2026 | Duato JoaquinCEO and Chairman of the Board, Director | Exercised options | 123,291 | $14.3M |
| August 13, 2026 | Duato JoaquinCEO and Chairman of the Board, Director | Sold | 20,976 | $5.5M |
Who owns JNJ
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Vanguard Capital Management13G, passive | 7.49% | May 1, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 4,673 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 212,098,264 | -1,287,282 |
| Vanguard Capital Management LLC | 157,226,374 | +621,004 |
| State Street Corp | 133,776,025 | +299,737 |
| Vanguard Portfolio Management LLC | 64,370,816 | +856,380 |
| Jpmorgan Chase & Co | 58,301,609 | -4,794,735 |
| Geode Capital Management, LLC | 59,086,417 | -78,445 |
| Morgan Stanley | 44,808,254 | +87,087 |
| Norges Bank | 31,825,084 | new |
| State Farm Mutual Automobile Insurance Co | 31,590,952 | 0 |
| Northern Trust Corp | 28,792,064 | -527,605 |
| Bank of America Corp | 23,438,141 | -2,078,556 |
| Fmr LLC | 22,595,566 | -2,176,262 |
| Wellington Management Group Llp | 22,588,696 | +2,513,321 |
| Bank of New York Mellon Corp | 21,683,347 | -138,615 |
| Goldman Sachs Group Inc | 19,722,544 | +1,665,497 |
| Legal & General Group Plc | 19,286,904 | -60,958 |
| Charles Schwab Investment Management Inc | 19,126,165 | -51,054 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 18,416,123 | -1,211,990 |
| Wells Fargo & Company | 17,374,433 | +448,979 |
| Invesco Ltd. | 15,674,093 | +627,188 |
Insiders
12 insiders reported holding 790,972 shares in total, about $208.6M at the last price.
| Holder | Shares |
|---|---|
| Duato JoaquinCEO and Chairman of the Board, Director | 306,81930,852 held indirectly |
| Taubert Jennifer LEVP, WWC. Innovative Medicine | 194,451 |
| Wengel Kathryn EEVP, Chief TO and Risk Officer | 114,288 |
| Swanson James D.EVP, CIO | 25,698 |
| Schmid TimothyEVP, WW Chair, MedTech | 25,447 |
| Reed John CEVP, Innovative Medicine, R&D | 24,911 |
| Decker Robert JVP Corporate Controller | 23,682 |
| Broadhurst VanessaEVP, Global Corp Affairs | 23,003 |
| Mulholland KristenEVP, Chief HR Officer | 19,830 |
| Forminard ElizabethEVP, Chief Legal Officer | 16,994 |
Questions about JNJ
What does Johnson & Johnson do?
Johnson & Johnson researches, develops, and manufactures prescription pharmaceuticals and medical devices. Its products include medicines for immunology, oncology, and infectious diseases, as well as surgical instruments and orthopedic implants. These are sold to hospitals, physicians, and pharmacies. The company is known for medical technology and healthcare products. Its shares trade on NYSE under the ticker JNJ.
What is Johnson & Johnson's net worth?
Johnson & Johnson has a market value (market cap) of $635.6B at the latest share price, and shareholders' equity of $85B on its balance sheet at June 28, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Johnson & Johnson profitable?
Yes. Over the twelve months to June 28, 2026 it reported net income of $21B on revenue of $97.9B, a net margin of 21.5%.
How much revenue does Johnson & Johnson make?
Over the twelve months to June 28, 2026 Johnson & Johnson reported revenue of $97.9B. That is 8.1% more than a year earlier.
When did Johnson & Johnson last report?
Its most recent periodic report is the quarterly report (10-Q) filed on July 23, 2026. It covers the period to June 28, 2026. Its newest filing of any kind is the insider trade from September 10, 2026.
When is Johnson & Johnson's next earnings report?
Johnson & Johnson's next report is expected around October 13, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Does Johnson & Johnson pay a dividend?
Yes. Johnson & Johnson paid dividends of $5.14 per share in fiscal 2025, a yield of 1.95% at the current price.
Similar companies
Compare JNJ with
Follow JNJ
Get an email when Johnson & Johnson files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Johnson & Johnson tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.